Letter to the Editor: Is Emricasan (IDN‐6556), an Oral Pan‐Caspase Inhibitor, Ready for Controlled Trials?
Sandeep Khurana, Harshit S. Khara – 2 May 2019
NOD‐like receptor C4 Inflammasome Regulates the Growth of Colon Cancer Liver Metastasis in NAFLD
Koichiro Ohashi, Zhijun Wang, Yoon Mee Yang, Sandrine Billet, Wei Tu, Michael Pimienta, Suzanne L. Cassel, Stephen J. Pandol, Shelly C. Lu, Fayyaz S. Sutterwala, Neil Bhowmick, Ekihiro Seki – 1 May 2019 – Nonalcoholic fatty liver disease (NAFLD) enhances the growth and recurrence of colorectal cancer (CRC) liver metastasis. With the rising prevalence of NAFLD, a better understanding of the molecular mechanism underlying NAFLD‐associated liver metastasis is crucial. Tumor‐associated macrophages (TAMs) constitute a large portion of the tumor microenvironment that promotes tumor growth.
First Do No Harm: Medication‐Related Problems Among Patients With Cirrhosis
Lydia Aye, Michael Volk – 1 May 2019
Reply
Raymond J. Lynch, Fei Ye, Quanhu Sheng, Zhiguo Zhao, Seth J. Karp – 30 April 2019
Con: Liver Biopsy Remains the Gold Standard to Evaluate Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Daniel Berger, Vishal Desai, Sujit Janardhan – 30 April 2019
Family Counseling for Hepatitis B and Hepatitis C
Tatyana Kushner, Rhoda S. Sperling, Douglas Dieterich – 30 April 2019
Approach to Hyponatremia in Cirrhosis
Bashar Attar – 30 April 2019
Pro: Noninvasive Imaging Has Replaced Biopsy as the Gold Standard in the Evaluation of Nonalcoholic Fatty Liver Disease
Shaham Mumtaz, Nathan Schomaker, Natasha Von Roenn – 30 April 2019
Patients With Chronic Liver Disease/Cirrhosis Should Not Take Statin Medications
Christopher Kasia, Steven J. Scaglione – 30 April 2019